"

From 2013.igem.org

Revision as of 21:03, 27 September 2013 (view source) Carlosaxg (Talk | contribs) ← Older edit		Revision as of 21:04, 27 September 2013 (view source) Carlosaxg (Talk | contribs) Newer edit →
Line 29:		Line 29:
	<map name="schema_map">		<map name="schema_map">
-		+	<area shape="rect" coords="360,120,450,170" onmouseover="change_schema_image(image_0)">
-	<area shape="rect" coords="360,170,450,230" onmouseover="change_schema_image(image_1)" onmouseout="change_schema_image(image_0)>	+	<area shape="rect" coords="360,170,450,230" onmouseover="change_schema_image(image_1)">
	<area shape="rect" coords="360,250,450,310" onmouseover="change_schema_image(image_2)">		<area shape="rect" coords="360,250,450,310" onmouseover="change_schema_image(image_2)">
-	<area shape="rect" coords="360,300,450,360" onmouseouver="change_schema_image(image_3)">	+	<area shape="rect" coords="360,300,450,360" onmouseover="change_schema_image(image_3)">
	</map>		</map>
	</html>		</html>
	{{Team:UFMG Brazil/sponsor}}		{{Team:UFMG Brazil/sponsor}}

---

Revision as of 21:04, 27 September 2013

Death by heart diseases is very common worldwide, being Acute Coronary Syndrome (ACS) its main cause. This fact is deeply related to late diagnosis, which is usually made after the cardiac event had already occurred. We, from UFMG team, decided to explore this problem building a system capable of providing a precocious diagnosis for ACS based in 3 biomarkers:

• Brain Natriuretic Peptide (BNP),
• Trimethylamine-N-Oxide (TMAO),
• Ischemia Modified Albumin (IMA).

The main goal is to detect each of these biomarkers using our engineered E. coli by integrating the signals CFP, YFP and RFP produced when BNP, IMA and TMAO, respectively, are present in a sample of patient serum. This diagnosis is based on color intensity of the fluorescent proteins. So, we can establish the presence or absence and severity of ACS disease and predict earlier a myocardial event, thus providing information for fast treatment.

Our Sponsors